ArticleMaterials today. Bio2026
Diselenide-bridged mesoporous silica nanoplatform for baicalin delivery facilitates spinal cord injury repair via CHCHD2-mediated mitochondrial homeostasis restoration.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Baicalin and CNS-related diseases: new insights into neuroprotective potentials based on underlying mechanisms.Biochemistry and biophysics reports · 2026Review
- The Mechanism and Application of Traditional Chinese Medicine Nano-Formulations in the Treatment of Renal Fibrosis.International journal of nanomedicine · 2026Review
- Biotinylated ε-Polylysine-Cyclodextrin-Coated Mesoporous Silica Nanoparticles for Targeted pH-Responsive Baicalin Delivery.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the secondary phase of spinal cord injury (SCI), excessive accumulation of reactive oxygen species (ROS), mitochondrial dysfunction and amplified inflammatory cascades reinforce one another, forming a vicious cycle that drives progressive neuronal damage and limits functional recovery. To enhance lesion-site drug exposure and microenvironment-responsive delivery, we engineered a biomimetic nanoplatform (Ba@Se-MSN&BV2) by loading baicalin into diselenide-bridged mesoporous silica nanoparticles (MSNs) and cloaking them with BV2 microglial membranes, enabling lesion-targeted accumulation and ROS-triggered, on-demand release in ROS-rich lesions. In glutamate-injured HT22 cells and primary hippocampal neurons, Ba@Se-MSN&BV2 reduced ROS, partially restored mitochondrial membrane potential, suppressed apoptosis and enhanced neurite outgrowth, with protection generally exceeding that of free baicalin or Ba@Se-MSN. In lipopolysaccharide-stimulated BV2 microglia, the nanoplatform lowered IL-1β and TNF-α, increased Arg1 and IL-10 and shifted polarization toward an anti-inflammatory, reparative phenotype. In a mouse contusion SCI model, Ba@Se-MSN&BV2 preferentially accumulated at the lesion, mitigated oxidative burden, attenuated glial scarring and preserved axons and neurons. These tissue-level benefits were accompanied by sustained improvements in locomotor recovery and motor-evoked responses. Label-free quantitative proteomics highlighted CHCHD2 as a mitochondria-associated candidate that was downregulated in glutamate-injured neuronal cells and restored by Ba@Se-MSN&BV2. Knockdown/rescue assays supported a contributory role of CHCHD2 in the neuroprotective profile of the nanoplatform. Collectively, Ba@Se-MSN&BV2 mitigates oxidative-inflammatory imbalance during secondary SCI by coupling lesion-targeted homing, ROS-responsive baicalin release and CHCHD2-mediated mitochondrial stabilization, representing a lesion-matched, microenvironment-coupled nanotherapy with translational potential for post-SCI intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.